Biotech and Pharma

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”

The Broad Institute gene-sequencing lab used Roche equipment to read infants’ DNA genomes in less than four hours, cutting an hour off the previous Guinness World Record.

Praxis Precision Medicines said patients with a condition that causes uncontrollable shaking saw improvement using its experimental drug.

More than 3,000 people filed suit in the U.K. against a Kenvue subsidiary and Johnson & Johnson over baby powder.

JPMorgan Chase, Wells Fargo, and Goldman Sachs post quarterly earnings that top Wall Street estimates.

Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should sell itself.

Those looking to buy stocks right now should look for the ones that aren’t correlated to the artificial intelligence trade.

The company also reports earnings that slightly beat consensus estimates.

Broadcom is working with OpenAI to develop and deploy 10 gigawatts of custom artificial-intelligence accelerators, while MP Materials and other rare-earth stocks extend sharp gains.

The Trump administration has promised to delay sector-specific tariffs for both firms, and more drugmakers could join the club.

Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.

The Orbital Therapeutics deal is Bristol’s largest since February 2024.

Government shutdown hits day 10, U.S. begins Argentine rescue, Amazon Prime shoppers snapped up necessities, and more news to start your day.

Delta and PepsiCo report quarterly earnings that beat analysts’ estimates.

Lilly Endowment sold around $160 million worth of company stock on Oct. 6 and Oct. 7.

The food safety company discloses an unspecified number of layoffs.

The Dow Industrials index trails the S&P 500 and Nasdaq, but technical indicators are constructive.

Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of efruxifermin, it’s treatment for fatty liver disease.

Peter Marks was perhaps the best-known career official at the agency.

Amid a pricey market, Evercore wanted to find stocks that are less pricey but have staying power. Here’s how they did it and what they found.

The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.

There are signs that some of the structural problems that have dogged the sector are clearing.

Barron’s spoke with Dave Moore, executive vice president of U.S. operations, about Wegovy as a pill, rather than an injection.

HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.